Two MenB vaccines (Bexsero, Trumenba) are licensed in the US. Persons ≥10 years old at increased risk for meningococcal disease should receive a two-dose primary series of Bexsero or a three-dose primary series of Trumenba. Persons who remain at increased risk should receive a booster dose of the same MenB vaccine 1 year after completing the primary series and every 2-3 years thereafter. During an outbreak, previously vaccinated persons should receive a single booster dose if ≥1 year has passed since completion of the primary series.1

MenB vaccination is not routinely recommended for adolescents, but a two-dose MenB primary series may be considered for young adults 16-23 years old (preferably at 16-18 years) to provide short-term protection during a period of increased risk (e.g., among first-year college students living in dormitories).1

Recommendations for vaccination against N. meningitidis serogroups A, C, W, and Y (MenACWY) have remained unchanged.1,2 Two quadrivalent MenACWY vaccines (Menactra, Menveo) are currently available in the US; a third quadrivalent vaccine that uses tetanus toxoid as a protein carrier (MenQuadfi) was licensed in 2020 and is expected to become available in the first quarter of 2021.3 Healthy adolescents should receive one dose at age 11-12 years and a booster dose at age 16 years. Persons at increased risk for meningococcal disease can receive MenACWY vaccination beginning at age 2 months and should receive periodic booster doses.1